Physician profile
Junaid Arshad
NPI 1831506898
$32,488.42
in general payments reported to CMS, 2019-2025
40 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $651 · 2021: $1,323 · 2022: $1,612 · 2023: $144 · 2024: $14K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Honoraria: $5,462 · Food and Beverage: $1,640 · Travel and Lodging: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,527.50 |
| Honoraria | $5,462.00 |
| Food and Beverage | $1,639.93 |
| Travel and Lodging | $995.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $7,423.34 | 2021-2025 | Cabometyx |
| Boehringer Ingelheim International Gmbh | $6,990.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $6,587.19 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $5,051.65 | 2019-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,686.75 | 2021-2025 | |
| Daiichi Sankyo INC. | $1,526.80 | 2021-2025 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $839.78 | 2021-2025 | |
| Amgen INC. | $337.14 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $229.09 | 2020-2021 | |
| Celgene Corporation | $211.64 | 2019-2021 | |
| Seagen INC. | $160.79 | 2019-2021 | |
| Eisai INC. | $146.09 | 2020-2021 | |
| Tersera Therapeutics LLC | $130.53 | 2024 | Xermelo |
| Astellas Pharma US INC | $128.83 | 2020-2022 | |
| Incyte Corporation | $122.88 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $112.53 | 2020-2021 | |
| Abbvie INC. | $106.38 | 2020-2025 | Venclexta |
| Foundation Medicine, INC. | $98.03 | 2023 | |
| Glaxosmithkline, LLC. | $53.89 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $49.96 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $49.31 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $39.07 | 2021 | |
| Blueprint Medicines Corporation | $38.33 | 2020-2021 | |
| Genzyme Corporation | $36.22 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $35.60 | 2020 | |
| Morphosys, US INC. | $35.54 | 2021 | |
| Alexion Pharmaceuticals, INC. | $33.61 | 2021 | |
| Pfizer INC. | $31.89 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $28.77 | 2021 | |
| Deciphera Pharmaceuticals INC. | $23.08 | 2021 | |
| Gilead Sciences, INC. | $21.79 | 2021 | |
| Kite Pharma, INC. | $20.06 | 2020 | |
| Aurobindo Pharma USA, INC. | $19.29 | 2020 | |
| Dova Pharmaceuticals | $19.00 | 2021 | |
| Tactile Systems Technology INC | $18.19 | 2020 | |
| West Therapeutics Development, LLC | $17.13 | 2021 | |
| Emd Serono, INC. | $14.50 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $13.75 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.